Get There First with SurgeTM Discovery
Surge Discovery is the new, fully integrated therapeutic antibody discovery and engineering service from GigaGen.
Surge is the only method that interrogates every antibody from an immunized mouse to find you the best clinical candidates early in the discovery process. Surge fully replaces hybridoma and phage display.
Deeper Diversity - For each immunized mouse, Surge screens millions of B cells, capturing nearly 100% of antibodies generated post immunization and identifying more rare antibodies than any other method.
The Most Binders - Surge delivers hundreds of full-length antibodies with high binding affinity to various regions of the target, maximizing the odds of a successful clinical candidate and providing the backbone for a strong Intellectual Property footprint.
Highest Therapeutic Potential - Surge’s process maintains natural heavy and light chain pairing resulting in antibodies selected for affinity and stability in vivo, increasing therapeutic potential. Surge will put the most promising antibodies through its directed affinity maturation process if desired.
Faster - Within 6 weeks, Surge will deliver fully characterized monoclonal antibodies. Surge’s ultra-high throughput process generates a display library for each immunized mouse, screens for high affinity binders, and validates functionality.
Powered by a Proven, First-in-Class Technology
Surge succeeds where other methods can’t by creating naturally paired, millions diverse yeast display libraries from every mouse.
You provide the drug target.
Surge returns every high affinity binder from immunized mice, fully validated, within 6 weeks.
Let Surge tackle your toughest discovery problems. Contact us for more information.